Publications en collaboration avec des chercheurs de University of Texas MD Anderson Cancer Center (10)

2024

  1. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma

    Cancer Epidemiology, Vol. 92

2020

  1. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients with Osteosarcoma

    JAMA Oncology, Vol. 6, Núm. 5, pp. 724-734

  2. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2019

  1. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2015

  1. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

    Journal of the National Cancer Institute, Vol. 107, Núm. 12

2014

  1. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

    Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633

  2. RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner

    Molecular Oncology, Vol. 8, Núm. 2, pp. 196-206

  3. The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity

    Journal of Bone and Mineral Research, Vol. 29, Núm. 10, pp. 2287-2296

2012

  1. Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma

    American Journal of Respiratory and Critical Care Medicine, Vol. 186, Núm. 1, pp. 96-105

2010

  1. Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer

    Cancer Chemotherapy and Pharmacology, Vol. 65, Núm. 3, pp. 457-465